Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease

Gastroenterology

Volumn 151, Issue 2, 2016, Pages 278-287.e6

  Yaeger, Rona ^a   Shah, Manish A ^b   Miller, Vincent A ^c   Kelsen, Judith R ^d   Wang, Kai ^c,e   Heins, Zachary J ^a   Ross, Jeffrey S ^c   He, Yuting ^c   Sanford, Eric ^c   Yantiss, Rhonda K ^b   Balasubramanian, Sohail ^c   Stephens, Philip J ^c   Schultz, Nikolaus ^a   Oren, Moshe ^f   Tang, Laura ^a   Kelsen, David ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c FOUNDATION MEDICINE   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e ZHEJIANG CANCER HOSPITAL   (China)

^f WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Bowel Cancer; Cancer of the Ileum; IBD; Inflammatory Bowel Disease

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; HYBRID PROTEIN; ISOCITRATE DEHYDROGENASE 1; MYC PROTEIN; PROTEIN P53; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLITIS; COLORECTAL CANCER; CONTROLLED STUDY; CROHN DISEASE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; ILEUM CANCER; INFLAMMATORY BOWEL DISEASE; MALE; METASTASIS; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; ULCERATIVE COLITIS; COLORECTAL TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; COMPLICATION; GENETICS; GENOMICS; MIDDLE AGED; MUTATION; ONCOGENE MYC; PATHOLOGY; YOUNG ADULT;

ADULT; AGED; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; COMPARATIVE GENOMIC HYBRIDIZATION; CROHN DISEASE; FEMALE; GENES, MYC; GENOMICS; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; YOUNG ADULT;

EID: 84977673797     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.04.001     Document Type: Article

References (25)

1. 1 Beaugerie, L., Itzkowitz, S.H., Cancers complicating inflammatory bowel disease. N Engl J Med 372 (2015), 1441–1452.
2. 2 Higashi, D., Futami, K., Ishibashi, Y., et al. Clinical course of colorectal cancer in patients with ulcerative colitis. Anticancer Res 31 (2011), 2499–2504.
3. 3 Hyngstrom, J.R., Hu, C.Y., Xing, Y., et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol 19 (2012), 2814–2821.
4. 4 Leowardi, C., Schneider, M.L., Hinz, U., et al. Prognosis of ulcerative colitis-associated colorectal carcinoma compared to sporadic colorectal carcinoma: a matched pair analysis. Ann Surg Oncol 23 (2016), 870–876.
5. 5 Nitsche, U., Zimmermann, A., Spath, C., et al. Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. Ann Surg 258 (2013), 775–782 discussion 782–783.
6. 6 Watanabe, T., Konishi, T., Kishimoto, J., et al. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm Bowel Dis 17 (2011), 802–808.
7. 7 Cooks, T., Pateras, I.S., Tarcic, O., et al. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23 (2013), 634–646.
8. 8 Itzkowitz, S.H., Yio, X., Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287 (2004), G7–G17.
9. 9 Brentnall, T.A., Crispin, D.A., Rabinovitch, P.S., et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 107 (1994), 369–378.
10. 10 Greenwald, B.D., Harpaz, N., Yin, J., et al. Loss of heterozygosity affecting the p53, Rb, and mcc/apc tumor suppressor gene loci in dysplastic and cancerous ulcerative colitis. Cancer Res 52 (1992), 741–745.
11. 11 Fearon, E.R., Vogelstein, B., A genetic model for colorectal tumorigenesis. Cell 61 (1990), 759–767.
12. 12 Vogelstein, B., Kinzler, K.W., The path to cancer—three strikes and you're out. N Engl J Med 373 (2015), 1895–1898.
13. 13 Frampton, G.M., Fichtenholtz, A., Otto, G.A., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31 (2013), 1023–1031.
14. 14 Gnirke, A., Melnikov, A., Maguire, J., et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol 27 (2009), 182–189.
15. 15 Wagle, N., Berger, M.F., Davis, M.J., et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2 (2012), 82–93.
16. 16 Cheng, D.T., Mitchell, T.N., Zehir, A., et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 17 (2015), 251–264.
17. 17 The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (2012), 330–337.
18. 18 Muller, P.A., Trinidad, A.G., Caswell, P.T., et al. Mutant p53 regulates dicer through p63-dependent and -independent mechanisms to promote an invasive phenotype. J Biol Chem 289 (2014), 122–132.
19. 19 Ross, J.S., Wang, K., Khaira, D., et al. Comprehensive genomic profiling of clinically advanced colorectal carcinoma to reveal frequent opportunities for targeted therapies. J Clin Oncol, 33, 2015 abstr 3553.
20. 20 Muller, P.A., Vousden, K.H., Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25 (2014), 304–317.
21. 21 Ullman, T.A., Itzkowitz, S.H., Intestinal inflammation and cancer. Gastroenterology 140 (2011), 1807–1816.
22. 22 Robles, A.I., Traverso, G., Zhang, M., et al. Whole-exome sequencing analyses of inflammatory bowel disease-associated colorectal cancers. Gastroenterology 150 (2016), 931–943.
23. 23 He, T.C., Sparks, A.B., Rago, C., et al. Identification of c-MYC as a target of the APC pathway. Science 281 (1998), 1509–1512.
24. 24 Hartman, D.J., Binion, D., Regueiro, M., et al. Isocitrate dehydrogenase-1 is mutated in inflammatory bowel disease-associated intestinal adenocarcinoma with low-grade tubuloglandular histology but not in sporadic intestinal adenocarcinoma. Am J Surg Pathol 38 (2014), 1147–1156.
25. 25 Yan, H., Parsons, D.W., Jin, G., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 (2009), 765–773.